This issue begins with 2 short contributions from readers. The issue starts with a commentary on the use of chemoprotectants-agents that can protect normal cells from damage because of chemotherapy drugs. The authors, headed by Gopabandhu Jena of the National Institute of Pharmaceutical Education and Research in India, specifically advocate the use of the new disciplines of toxicogenomics and metabolomics in research on new chemoprotectants. This perspective may contribute to rational drug design of chemoprotective as well as chemosensitizing agents and would be an intriguing addition to the strategy we commonly see discussed in Integrative Cancer Therapies of evaluating well-known natural products for chemoprotective activity. Amirhossein Sahebkar and Mehrdad Iranshahi have submitted a brief letter on the possible 5-lipoxygenase activity of prenylcoumarins, phytochemicals found in plants of the citrus and carrot families, and especially in citrus fruits. 5-Lipoxygenase is an important cancer prevention and possibly cancer treatment target, and their suggestion certainly deserves further consideration.
The venerable Ayurvedic herb Alstonia scholaris begins the regular articles for this issue. The herb is reviewed by Manjeshwar Baliga, who points out that it has been traditionally used to treat cancer for centuries. In line with our first article, extracts or phytochemicals extracted from this species have shown both chemoprotection and chemosensitization activity in animal studies-as well as radioprotection and radiosensitization! Obviously, there is a long way to go before these findings can be directly applied to clinical situations, but this review certainly emphasizes the versatile and multitargeted nature of therapeutic herbs.
Christopher Jehn and colleagues at the University Hospital Charité in Berlin examined the relationships of interleukin-6 (IL-6), disorders in the hypothalamus-pituitaryadrenal (HPA), axis and depression in cancer patients. Diurnal cortisol variation is a standard measure for dysfunction in the HPA axis. Jehn explores the correlations of IL-6 and cortisol variation in populations of depressed and nondepressed cancer patients in this important article. It is interesting to note the linkage of IL-6, an inflammatory mediator that can be changed by diet or supplementation, with emotional state. This study highlights the complex and interdependent nature of biochemistry and overall quality of life in cancer patients.
The article by Moshe Frenkel and colleagues at M. D. Anderson Cancer Center shows the power of even a relatively simple and straightforward integrative medicine consultation service at a major cancer treatment facility. This study evaluated the basic intervention of the Place . . . of Wellness, M. D. Anderson's integrative clinic, which is a one-time consultation on use of complementary and alternative therapies for cancer. Patients who returned for second clinic visits after their initial consultation reported several positive outcomes from the consultation, especially in the area of encouragement and empowerment to adopt healthful practices. Evaluating active integrative medicine programs for cancer patients is a critical step in the effort to incorporate integrative therapies into cancer care, and we salute these authors for undertaking this study.
The next article also comes from the integrative program of a major medical center, the Zakim Center for Integrative Therapies at the Dana-Farber Cancer Institute. Lu Weidong and colleagues in this case series report summarize acupuncture therapy performed for clinic patients with head and neck cancer who were suffering from side effects of chemoradiation therapy. Patients reported a variety of benefits from acupuncture, including improvements in swallowing and xerostomia. This certainly suggests that a formal clinical trial of acupuncture for this indication is in order. Acupuncture continues to show a wide variety of benefits for cancer patients, and we hope to see it more widely incorporated in hospitals around the country as evidence of its benefits broadens.
The concept of zheng, or disease syndromes in traditional Chinese medicine (TCM), dictates that 2 patients with the same type of tumor or other disease may not necessarily receive the same treatment, because of differences in the syndrome each patient manifests, based on the common observations of TCM such as yin, yang, heat, deficiencies in the TCM organs, and other such characteristics. The concept is not unlike that of the emerging Western medicine paradigm of "personalized medicine," but has been subjected to much less biological evaluation. Hai-Yan Dai and colleagues at Fudan University take a creative approach to studying the concept of zheng at a biological and molecular level by establishing 2 mouse tumor lines with different zheng-one manifesting Damp heat and the other Spleen deficiency. They then correlate molecular and growth characteristics of these tumor lines. This is an innovative way to approach an analysis of TCM from a viewpoint comprehensible to the Western-trained physician. We hope more articles of this type will appear in the future.
Chin-Wen Chi and colleagues at the Taipei Veterans General Hospital explore the antileukemic effects of the woody vine Mucuna macrocarpa, a species of the Southeast Asian flora that is used for a variety of hematologic ailments. Both in vitro and in vivo studies are summarized in this article. Because of the poor prognosis and limitations on treatment options of some of the acute leukemias, continuing search for new therapies is a high priority. We are pleased to see this search extended further through the plants of TCM.
